Windtree Therapeutics, Inc. (NasdaqCM:WINT) acquired All of the assets of Varian Biopharmaceuticals, Inc. on April 2, 2024. As part of consideration (i) on April 2, 2024, the Company issued a total of 5,500 shares of the Company?s Series B Convertible Preferred Stock, par value $0.001 per share (the ?Series B Preferred Stock?), to certain creditors of Varian and (ii) agreed to pay up to $2.3 million in milestone payments upon the achievement of certain regulatory and clinical development milestones with the Company having the option to pay such milestone payments either in cash or the Company?s common stock, par value $0.001 per share (the ?Common Stock?). The Windtree Therapeutics, Inc. also assumed all liabilities arising on or after April 2, 2024 (the ?Closing Date?), relating to the research, development, manufacturing, registration, commercialization, use, handling, supply, storage, import, export or other disposition or exploitation of any and all products associated with the Transferred Assets.

Windtree Therapeutics, Inc. (NasdaqCM:WINT) completed the acquisition of All of the assets of Varian Biopharmaceuticals, Inc. on April 2, 2024.